Laidlaw Group’s Edwards Lifesciences EW Stock Holding History

Laidlaw Group’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$7M	Sell	294,684 -35,010	-11%	-$790K	3.33%	4
2015 Q1	$7.83M	Sell	329,694 -5,100	-2%	-$114K	3.72%	3
2014 Q4	$7.11M	Sell	334,794 -6,786	-2%	-$136K	3.38%	4
2014 Q3	$5.82M	Sell	341,580 -2,370	-0.7%	-$37.4K	2.89%	6
2014 Q2	$4.92M	Buy	343,950 +840	+0.2%	+$11.4K	2.45%	12
2014 Q1	$4.24M	Buy	+343,110	New	+$3.96M	2.22%	15

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Laidlaw Group's EW Position: Q2 2015 in Review

Laidlaw Group reduced its Edwards Lifesciences (EW) stake by 11% in Q2 2015, selling an estimated $790K and leaving 294,684 shares worth $7M. The position accounts for 3.33% of the portfolio, ranked #4.

Laidlaw Group first reported a position in EW in Q1 2014 and has held it in 6 quarters since. The position peaked at $7.83M in Q1 2015. 579 funds tracked by Wall St. Rank hold EW as of Q2 2015.

Laidlaw Group held 294,684 shares of Edwards Lifesciences worth $7M as of Q2 2015.
Laidlaw Group sold 35,010 Edwards Lifesciences shares in Q2 2015, an estimated $790K.
Edwards Lifesciences made up 3.33% of Laidlaw Group's portfolio in Q2 2015, its #4 holding.
Laidlaw Group first reported a position in Edwards Lifesciences in Q1 2014 and has held it in 6 quarters since.
Laidlaw Group's Edwards Lifesciences position peaked at $7.83M in Q1 2015.
579 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2015.

Based on Laidlaw Group's 13F filing for Q2 2015, filed 31 Jul 2015.